Navigation Links
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Date:12/21/2009

nd breast cancer. OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

Clusterin is a protein that is over-produced in several types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Preclinical and other data suggest that clusterin promotes cell survival. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration. Since increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma, OGX-011 may have broad market potential to treat many cancer indications and disease stages.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is the world's leading generic pharmaceutical company and is among the top 20 pharmaceutical companies in the world. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase II clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase I clinical develop
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... While administrative claims and other data ... a relatively long period of time, there has ... of these ‘big data’ for comparisons of interventions ... powerful computer technology with the plethora of data ... significant promise for identifying optimal interventions for specific ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... IL (PRWEB) July 30, 2014 ... Arun Athmanathan will present his findings on corn ... Energy conference this week in Washington, D.C. ... of Energy conference is a testament to the ... John Caupert said. “Thanks to the foresight and ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... that allow nanoparticles to assemble themselves into designer materials ... of Iowa State University and the Ames Laboratory reports ... Science . Travesset, an associate professor of physics ... of Energy,s Ames Laboratory, writes in the journal,s Perspectives ...
... today announced that Jeff Liter has been appointed as ... "Jeff,s diverse background in all aspects of corporate development ... Said Matt McManus, President and CEO, PrimeraDx.  "PrimeraDx,s strategy ... Plex system in the MDx market and define ...
... from the Faculty of Biology and Biotechnology at the ... of Biological Chemistry explaining why enzymes used for ... In collaboration with researchers from Berlin, they used spectroscopic ... that lead to the inactivation of the enzyme,s iron ...
Cached Biology Technology:Iowa State, Ames Lab physicist says nanoparticle assembly is like building with LEGOs 2PrimeraDx Appoints Jeff Liter as VP of Corporate Development 2If oxygen becomes the undoing of proteins 2
(Date:7/29/2014)... climate warms and sea ice retreats, the North is ... increasingly open water which is predicted to extend across ... century. Storms thus have the potential to create Arctic ... and unpredictable element to the region. , A University of ... the middle of the Arctic Ocean, and detected house-sized ...
(Date:7/29/2014)... journey to the edge of science, Clment Vidal takes ... Beginning and the End: Does our universe have a ... we alone in the universe? What is the role ... in science and committed to philosophical rigor, the book ... life is not an accident, but may well be ...
(Date:7/29/2014)... have developed an easier method to create DNAprotein ... involved in diagnosing diseases. , DNA linked to ... partnership that can be used in diagnostic techniques, ... tag proteins with DNA can be used ... visualisation of biological material. The method also provides ...
Breaking Biology News(10 mins):Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3Book: 'The Beginning and the End' 2New method provides researchers with efficient tool for tagging proteins 2
... in the FASEB Journal ( http://www.fasebj.org ) ... because scientists have moved closer toward correcting the root ... Specifically researchers identified a protein (G6PD protein) and its ... promote the growth of cells which produce and release ...
... pregnant and looking for an excuse to eat bacon and eggs, ... January 2010 print issue of the FASEB Journal ( ... shows that choline plays a critical role in helping fetal brains ... pork, as well as chicken eggs. "Our study in ...
... 2010) Autism Speaks applauds the consensus statement and ... (GI) disorders in children with autism spectrum disorders (ASD) ... in advancing physician awareness of unique challenges in the ... to see the publication of these consensus recommendations. Autism ...
Cached Biology News:New discovery by Harvard scientists aims to correct cellular defects leading to diabetes 2Finally, an excuse for pregnant women to eat bacon and eggs 2Pediatrics GI recommendations -- first step to guidelines for children with autism 2Pediatrics GI recommendations -- first step to guidelines for children with autism 3
Request Info...
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
... Immunogen: Synthetic peptide derived from the ... bovine Math-2. Specificity: Specific for ... Rat (positive controls: human U251 A172 ... and rat brain homogenates)Storage: Store at ...
Biology Products: